ArticleBreast cancer research and treatment2024

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.

Gretchen Kimmick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.